Envista (NVST) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Envista (NYSE: NVST):

• 9/10/2026 – Envista had its “market perform” rating reaffirmed by BMO Capital Markets.
• 9/5/2026 – Envista was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 9/3/2026 – Envista was given a new $32.00 price target by Deutsche Bank Aktiengesellschaft.
• 9/3/2026 – Envista was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $32.00 price target on the stock, up from $29.00.
• 8/22/2026 – Envista was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/7/2026 – Envista was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/6/2026 – Envista was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/6/2026 – Envista was given a new $23.00 price target by Morgan Stanley.
• 8/6/2026 – Envista was given a new $34.00 price target by Robert W. Baird.
• 8/6/2026 – Envista was given a new $29.00 price target by Mizuho.
• 8/6/2026 – Envista had its “neutral” rating reaffirmed by Piper Sandler. They now have a $28.00 price target on the stock, up from $26.00.
• 7/29/2026 – Envista had its price target raised by Piper Sandler from $25.00 to $26.00. They now have a “neutral” rating on the stock.

Insider Buying and Selling at Envista

In other news, SVP Mischa Reis sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares in the company, valued at $751,327.50. This trade represents a 22.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by company insiders.

Envista Holdings Corporation is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral-care professionals.

Envista’s portfolio includes dental imaging and diagnostic systems, digital dentistry and CAD/CAM solutions, dental implants, orthodontic brackets and wires, clear aligner products, endodontic instruments, restorative materials, infection-prevention products and other dental consumables.